Affordable Access

deepdyve-link
Publisher Website

Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).

Authors
  • Murakami, Naoka1
  • Ding, Yanli2
  • Cohen, David J3
  • Chandraker, Anil K1
  • Rennke, Helmut G2
  • 1 Schuster Transplant Research Center, Brigham and Women's Hospital, Boston, Massachusetts.
  • 2 Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • 3 West Palm Beach VA Medical Canter, West Palm Beach, Florida.
Type
Published Article
Journal
Transplant Infectious Disease
Publisher
Wiley (Blackwell Publishing)
Publication Date
Oct 01, 2018
Volume
20
Issue
5
Identifiers
DOI: 10.1111/tid.12959
PMID: 29968947
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Direct-acting antiviral agents (DAAs) are very effective therapy for chronic hepatitis C infection, and have revolutionized the treatment of hepatitis C in kidney allograft recipients. Although well tolerated in general, rare renal complications have been reported. We describe a case of recurrent membranous nephropathy and acute cellular rejection in a kidney allograft recipient after DAA (ledipasvir/sofosbuvir) therapy, whose allograft function had been stable for more than 30 years. The patient was presented with nephrotic range proteinuria with stable creatinine. The kidney allograft biopsy revealed recurrent membranous nephropathy with fine granular deposits of IgG1/IgG4 codominance and positive phospholipase A2 receptor (PLA2R) staining. The patient was treated with pulse steroid and rituximab, leading to a decrease in proteinuria. As DAAs are more frequently used, physicians should be aware of immune-related renal complications. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times